Subjects with another primary malignancy that has not been in remission for at least  years, with the exception of non-melanoma skin cancer, curatively treated localized prostate cancer with non-detectable prostate-specific antigen, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou (Pap) smear, and thyroid cancer (except anaplastic).
History of another primary malignancy that has not been in remission for at least  years. The following are exempt from the -year limit: non-melanoma skin cancer, completely resected Stage  solid tumor with low risk for recurrence, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.
History of another primary malignancy that has not been in remission for at least  year (the following are exempt from the -year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, curatively treated superficial bladder cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear)
History of another primary malignancy that has not been in remission for at least  years (the following are exempt from the -year limit: non-melanoma skin cancer, fully excised melanoma in situ [stage ], curatively treated localized prostate cancer, and cervical or breast carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou [PAP] smear);
History of another invasive malignancy that has not been in remission for at least  years. Exceptions to the year limit include non-melanoma skin cancer, curatively treated localized prostate cancer, ductal carcinoma in situ, and cervical cancer in situ on biopsy or squamous intraepithelial lesion on PAP smear.
History of another primary malignancy that requires intervention beyond surveillance or that has not been in remission for at least  year (the following are exempt from the  year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou [PAP] smear)
History of another primary malignancy that has not been in remission for at least  years (the following are exempt from the -year limit: non-melanoma skin cancer, fully excised melanoma in situ [stage ], curatively treated localized prostate cancer, and cervical or breast carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou [PAP] smear)
CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION: History of another primary malignancy that has not been in remission for at least  years with the following exceptions: nonmelanoma skin cancer, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on pap smear, or other malignancy considered by the investigator to have a low risk of relapse or progression
History of other primary malignancy not in remission for at least  years (The following are exempt from the -year limit: nonmelanoma skin cancer, definitively treated stage  solid tumor with low risk for recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear)
History of another primary malignancy that has not been in remission for at least  years; (the following are exempt from the -year limit: nonmelanoma skin cancer, fully excised melanoma in situ [stage ], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear)
History of another primary malignancy that has not been in remission for at least  years (the following malignancies are exempt from the  year limit: non-melanoma skin cancer, fully-excised melanoma in situ [stage ], curatively treated, localized prostate cancer, and cervical carcinoma in situ in biopsy or a squamous intraepithelial lesion on Papanicolau [PAP] smear)
Patients with a history of other malignancies during the past three years. (The following are exempt from the three-year limit: non-melanoma skin cancer, Lymphomatoid papulosis, curatively treated localized prostate cancer, curatively treated localized breast cancer, resected thyroid cancer, biopsy proven cervical intraepithelial neoplasia or cervical carcinoma in situ).
A history of any other primary malignancy that has not been treated with curative intent and that has not been in complete remission for at least  years (exempt from the two year limit are non-melanoma skin cancer and cervical carcinoma in-situ on biopsy or a squamous intraepithelial lesion on PAP smear).
History of another invasive malignancy that has not been in remission for at least  years. Exceptions to the  year limit include nonmelanoma skin cancer, curatively treated localized prostate cancer, and cervical cancer in situ on biopsy or squamous intraepithelial lesion on PAP smear
Second primary malignancy that has not been in remission for greater than  years. Treated non-melanoma skin cancer, cervical carcinoma in situ on biopsy, or squamous intraepithelial lesion on PAP smear, localized prostate cancer (Gleason score < ), or resected melanoma in situ are exceptions and do not require a  year remission.
cervical carcinoma in situ on biopsy or squamous intraepithelial lesion on Pap smear; and
History of another primary malignancy that has not been in remission for at least  years (the following are exempt from the -year limit: non-melanoma skin cancer, fully excised melanoma in situ [stage ], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou [PAP] smear)
History of another primary malignancy that has not been in remission for at least  years. (The following are exempt from the -year limit: nonmelanoma skin cancer, completely resected stage  solid tumor with low risk for recurrence, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.)
Patient with a history of other malignancies during the past three years; (the following are exempt from the -year limit: non-melanoma skin cancer, melanoma in situ, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou [PAP] smear)
Patients with another primary malignancy that has not been in remission for at least  years, unless approved by the Idera Medical Monitor. The following are exempt from the -year limit: non-melanoma skin cancer, curatively treated localized prostate cancer with non-detectable prostate-specific antigen, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou (Pap) smear, and thyroid cancer (except anaplastic).
History of another primary malignancy not in clinical remission; except adequately treated patients with completely resected in situ carcinoma, such as nonmelanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou (Pap) smear, or localized prostate cancer with prostate-specific antigen (PSA) <  ng/ml
History of another invasive malignancy that has not been in remission for at least  year. (Exceptions are nonmelanoma skin cancer, curatively treated localized prostate cancer, ductal carcinoma, and cervical carcinoma or a squamous intraepithelial lesion on PAP smear).
History of another primary malignancy not in remission for at least  years (the following are exempt from the -year limit: nonmelanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear)
History of another primary malignancy that has not been in remission for at least  years (the following are exempt from the -year limit: non-invasive nonmelanoma skin cancer, fully excised melanoma in situ [stage ], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou [PAP] smear)
History of another primary malignancy that has not been in remission for at least  years (the following are exempt from the -year limit: non-melanoma skin cancer, fully excised melanoma in situ [stage ], curatively treated localized prostate cancer, and cervical or breast carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou [PAP] smear)
Second primary malignancy that has not been in remission for greater than  years, with the exception of non-melanoma skin cancer, cervical carcinoma in situ,or squamous intraepithelial lesion on PAP smear, localized prostate cancer (Gleason score <), or resected melanoma in situ.
History of another primary malignancy that has not been in remission for at least  years; (Note: The following are exempt for the -year limit: nonmelanoma skin cancer, fully excised melanoma in situ [stage ], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou [PAP] smear)
History of another invasive malignancy that has not been in remission for at least  years. Exceptions: nonmelanoma skin cancer, curatively treated localized prostate cancer, and cervical cancer in situ on biopsy or squamous intraepithelial lesion on PAP smear.
